High-dose chemotherapy and autologous stem cell transplantation for relapsed or refractory nodular lymphocyte predominant XXXX .

@entity1 @entity12497 @entity1667 @entity900 @entity2879 @entity2592 @entity3600 @entity1892 @entity3601 @entity2408 @entity978
UNASSIGNED: @entity978 ( @entity978 ) is a distinct subtype of @entity978 . We report our results of relapsed/refractory @entity978 @entity1 who received high-dose chemotherapy and autogenic stem cell transplantation (HDC auto- @entity12497 ). Seventeen @entity978 @entity1 received HDC auto- @entity12497 (1996-2014): male 14 and female 3, with median age at diagnosis of 22  years, at HDC auto- @entity12497 28  years (15-58  years). At the time of relapse/progression, 13 (76  %) had @entity978 and 4 (24  %) had transformed diffuse large @entity1892 . The reason for HDC auto- @entity12497 was refractory @entity978 in 12 @entity1 and relapsed in 5 @entity1 . Salvage chemotherapy was @entity2879 , @entity1667 , @entity900 , and @entity2592 (ESHAP); eight @entity1 also received rituximab with ESHAP. HDC was @entity3600 , @entity2879 , @entity2592 , and @entity3601 (BEAM). Post-auto- @entity12497 , complete remission was achieved in 14 (82  %), partial remission in 1 (6  %), and progressive disease in 2 (12  %) @entity1 . The median follow-up is 63  months from auto- @entity12497 (6-124  months). Of the nine @entity1 who received only ESHAP, four had post-auto- @entity12497 events versus no event in all eight @entity1 who received rituximab   +   ESHAP. Kaplan-Meier estimates of 5-year event-free survival for the whole group is 76  %: @entity2408   +   salvage (100  %) versus salvage alone (56  %), P   =   0.041. Overall survival is 94  %: 100 versus 89  %, respectively, P   =   not significant (NS). Even in refractory @entity978 @entity1 , long-term disease-free survival is possible after HDC auto- @entity12497 . Post-auto- @entity12497 relapse or progression can still be managed with chemo/chemo   +   immunotherapy/radiation. These encouraging results of rituximab in salvage setting should be explored further in a clinical trial setting for this @entity1 population.
